Insider Buying: CSL Limited (ASX:CSL) Insider Purchases 132 Shares of Stock

CSL Limited (ASX:CSL) insider Megan Clark acquired 132 shares of the company’s stock in a transaction that occurred on Wednesday, February 19th. The stock was acquired at an average price of A$264.85 ($168.69) per share, with a total value of A$34,959.94 ($22,267.48).

CSL Price Performance

The stock has a market cap of $77.43 billion, a PE ratio of 28.02, a P/E/G ratio of 1.29 and a beta of 0.32. The company has a debt-to-equity ratio of 64.46, a quick ratio of 1.68 and a current ratio of 1.86.

CSL Increases Dividend

The firm also recently disclosed a Interim dividend, which will be paid on Tuesday, April 8th. Investors of record on Tuesday, April 8th will be paid a $2.073 dividend. This is a boost from CSL’s previous Interim dividend of $1.83. The ex-dividend date is Sunday, March 9th. This represents a dividend yield of 0.81%. CSL’s payout ratio is currently 50.38%.

CSL Company Profile

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.